Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly stock jumped Friday after unveiling a nearly $2 billion takeover that could bolster its efforts among weight-loss drugs.

Eli Lilly Unveils A Nearly $2 Billion Deal To Leap Ahead In Weight Loss

The deal is Eli Lilly's latest attempt to capitalize on the weight loss industry gold rush, which was sparked by demand for Novo Nordisk's Wegovy and Ozempic.

Eli Lilly to acquire obesity drug maker Versanis for $1.9 billion

Eli Lilly (NYSE: LLY ) stock is a hot topic among traders on Friday after the company announced its acquisition of Versanis Bio . Versanis Bio is a clinical-stage biopharmaceutical company developing treatments for cardiometabolic diseases.

LLY Stock Alert: What to Know as Eli Lilly Acquires Versanis Bio

Eli Lilly and Co (NYSE:LLY) announced on Friday that it will buy privately held drug developer Versanis for up to $1.93 billion, in a bid to improve its portfolio of obesity drugs. Under the terms of the deal, Versanis shareholders could receive $1.93 billion in cash, which includes an upfront payment and subsequent payments upon achieving certain development and sales milestones.

Eli Lilly spends up to $1.93B to acquire obesity drug developer Versanis

Versanis shareholders could receive as much as $1.925 billion in cash, which will consist of an upfront payment and additional payments if certain milestones are reached.

Eli Lilly to Acquire Versanis Bio, Maker of Obesity Treatment

Eli Lilly and Co said on Friday it will acquire privately held drug developer Versanis for up to $1.93 billion, in a bid to boost its portfolio of obesity drugs.

Lilly to buy Versanis for up to $1.93 bln to boost obesity drug portfolio

Eli Lilly and Co. LLY, -1.34% will acquire Versanis Bio, a private clinical-stage biopharma company focused on new treatments for cardiometabolic diseases, the companies said in a release Friday. Versanis is developing a monoclonal antibody called bimagrumab that is being studied alone and in combination with the popular weight-loss drug semaglutide to potentially further reduce fat mass while preserving muscle.

Eli Lilly to acquire Versanis Bio, expanding obesity-treatment pipeline

Medicxi co-led Company's US$70 million Series A less than 2 years ago Third Medicxi portfolio exit to US biopharma in last 12 months LONDON, GENEVA and JERSEY, British Isles, July 14, 2023 /PRNewswire/ -- Medicxi, a leading European life sciences investment firm, announces that its portfolio company, Versanis Bio, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases, has entered into a definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY). Under the terms of the agreement, which is subject to customary conditions, Versanis shareholders would receive up to $1.925 billion USD in cash, inclusive of an upfront payment and subsequent payments upon achievement of certain development and sales milestones.

Medicxi asset-centric portfolio company Versanis Bio to be acquired by Lilly to improve patient outcomes in cardiometabolic diseases

INDIANAPOLIS and NEW YORK , July 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of cardiometabolic diseases. Versanis' lead asset is bimagrumab, a monoclonal antibody that binds activin type II A and B receptors to block activin and myostatin signaling.

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

Warren said the report shows that Congress needs to take additional steps to reduce the excessive prices of insulin from Eli Lilly, Sanofi and Novo Nordisk.

Uninsured Americans pay high costs for an insulin Eli Lilly vowed to price at $25, Sen. Warren says

Novo Nordisk

An overweight world is hungry for obesity treatments, driving big forecasts for weight loss drugs. For now, two pharmaceutical stocks own the market.

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?

Americans without health insurance pay an average of $98 for Eli Lilly's generic insulin despite the company's May 1 pledge to cut its list price to $25 per vial, according to a survey of more than 300 U.S. pharmacies by U.S. Senator Elizabeth Warren's office released on Thursday.

Uninsured US patients pay up to $330 for Eli Lilly's $25 insulin, Senator Warren says

AbbVie

Amgen

DiCE Molecules Holding LLC

Horizon Pharma

Pfizer

Seagen

The brisk pace of biopharmaceutical deal making seen in the first half of this year may only accelerate in the months ahead, even as regulators take a hard look at some of the bigger deals, analysts say.

Drugmakers' deal making will plow ahead despite antitrust scrutiny, analysts say

The European Medicines Agency said Tuesday it's reviewing data on the risk of suicidal thoughts and self-harm stemming from the use of the new medicines called GLP-1 receptor agonists, that are used to treat Type 2 diabetes and obesity. The review comes after Iceland's medical regulator reported self-injury and suicidal thoughts in people using Ozempic, Saxenda and Wegovy.

EU medicines regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm

Eli Lilly stock and Novo Nordisk stock skidded Tuesday on a report most patients taking weight loss drugs like Wegovy stopped within a year.

The Damaging Report That Sent Weight-Loss Kingpins Novo Nordisk, Eli Lilly Into A Tailspin

INDIANAPOLIS , July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast will begin at 1:30 p.m.

Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC

Eli Lilly's prospective drugs and existing obesity/diabetes medicines are strong. The company's dividend has lots of room for growth.

3 Reasons to Buy Eli Lilly, and 1 Reason to Sell

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of DICE Therapeutics, Inc. (NasdaqGM: DICE) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of DICE will receive $48.00 in cash for each share of DICE that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE

BETHLEHEM, Pa.--(BUSINESS WIRE)--ABEC, a leader in engineered solutions and services for biotech manufacturing, announced it will deliver multiple Custom Single Run (CSR®) single-use systems to Eli Lilly's next-generation biopharmaceutical manufacturing facility in Limerick, Ireland. ABEC's large-scale CSR Bioreactors will be at the heart of the facility, and ABEC will also manufacture, test, and install large-scale CSR GenMix systems. Equipment deliveries are scheduled for Q3 2023. Lilly selec.

Eli Lilly Selects ABEC for World's Largest Single-Use Biopharmaceutical Manufacturing Facility

Eli Lilly has seen a massive ramp-up in its diabetes, or better said weight loss, drug Mounjaro. Investors continue to price in further advancements on this front; the question is how much is priced in. I see the reason to get upbeat amidst impressive research results for the drug on weight loss, yet I am not willing to get involved here just yet.

Eli Lilly: Patients Get Skinnier, Profits Get Fatter

The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes YANTAI, China , July 9, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, announced a clinical research and supply agreement with Innovent Biologics ("Innovent")  (HKEX: 01801) .

RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors

Stocks of developers of fatty liver disease treatments had been on a tear until results from Eli Lilly's medication were published last week.

Obesity Drugs Won't Starve These Other Potential Blockbusters

INDIANAPOLIS , July 6, 2023 /PRNewswire/ -- Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that The New England Journal of Medicine  (NEJM) published detailed results from the BRUIN Phase 1/2 trial evaluating the efficacy and safety of an investigational use of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, in adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were previously treated with a BTK inhibitor. The NEJM publication provides additional clinical details from the data set that was presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lilly (LLY) continues to raise the bar on obesity drugs as latest data show that participants treated with these experimental drugs achieved mean weight reduction of up to 24%.

Can Eli Lilly's (LLY) Continue its Ride on Obesity Drug Wave?

Verve Therapeutics announced a partnership with Eli Lilly & Co., focusing on in-vivo gene editing technology, but investors remain concerned about the FDA's clinical hold on Verve's PCSK9 candidate VERVE-101. The partnership could provide Verve with financial stability through 2026, with the potential for an additional $465M based on achievements and sales-based royalties, but the company's valuation is primarily tied to the success of VERVE-101. Despite the partnership, the market's attention remains on the phase 1b study for VERVE-101, with many unpredictable risks.

News for Eli Lilly Stock (LLY)